Efficacy of docetaxel plus carboplatin combination chemotherapy for advanced non-small cell lung cancer.
- Author:
Wei WANG
1
;
Liqun SHANG
;
Xuechang LI
;
Feng WEN
;
Weian SONG
;
Jun LI
Author Information
- Publication Type:Journal Article
- From: Chinese Journal of Lung Cancer 2007;10(4):316-319
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUNDChemotherapy is one of the important treatment methods for advanced non-small cell lung cancer (NSCLC). The aim of this study is to evaluate the efficacy of docetaxel combined with carboplatin in treatment of advanced NSCLC.
METHODSSixty-four stage IIIB/IV NSCLC patients were treated with docetaxel (75 mg/m² intravenously, on day 1) and carboplatin (AUC=5 intravenously, on day 2).
RESULTSThe overall response rate (RR) was 42.6%, median survival time (MST) was 14 months, and 1-year survival rate was 45.23%. In initial treatment group, 1-year survial rate was 48.84% and MST was 14 months, and 37.89% and 12 months respectively in retreatment group (P=0.0233). The 1-year survial rate and MST of stage IIIB patients were 44.86% and 15 months, and 39.75% and 12 months respectively in stage IV patients (P=0.0354). There was no significant difference in efficacy between squamous cell carcinoma and adenocarcinoma patients. The major adverse effects were granulopenia, fatigue, nausea, vomiting and alopecia.
CONCLUSIONSThe combination of docetaxel and carboplatin has a high response rate and tolerable side effects in treatment of advanced NSCLC, which can be adopted as both the first-line and second-line treatment.